Breaking News, Collaborations & Alliances

Galapagos and MorphoSys Partner with Novartis

Novartis will cover development and commercialization costs of their joint program, MOR106

Galapagos NV and MorphoSys AG have entered into a worldwide, exclusive agreement with Novartis. Novartis will be responsible for the development and commercialization costs of their joint program MOR106.  MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys and Galapagos. Under the terms of the agreement, the parties will cooperate to broaden the existing development plan for MOR106 in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters